ProMetic Life Sciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ProMetic Life Sciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: axial	10/13/2017 9:39:59 AM
	of 250

Panmure Gordon — ProMetic Life Sciences *'Show me a drug developer that doesn’t experience delays, I’ll show you a company that does nothing* In the table below, we have compared the pipeline of Prometic with FibroGen and Galapagos. It is clear that Prometic has a larger, more varied and advanced pipeline than either. Yet it is trading a mere C$1.1bn market cap compared with over $4bn for FibroGen and Galapagos. We believe the shares will recover strongly as news that RyplazimTM has been approved is announced later this year.' __________________________________________________ — From zero to expected commercial launch ~3.5 years __________________________________________________ Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next